Target Gene/Pathway Pathway / Gene
Search results
Showing 1 to 10 of 73 entries
| No. | KEGG GENES | KEGG PATHWAY | KEGG DRUG | DrugBank | 指定難病告示番号 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 |
TNFSF13B
💬1. TNFSF13B
| 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis 4件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network ... | Belimumab
Belimumab
💬1. TNFSF13B
| Belimumab | 13件: 11 11, 13, 43, 44, 46, 49, 51, 53, 63, 66, 222, 296, 300 💬1. TNFSF13B
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2 |
CSF3R
💬2. CSF3R
| 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer 5件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, ... | Filgrastim
Filgrastim
💬2. CSF3R
| Filgrastim | 35件: 2 2, 6, 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬 35件: 2, 6, 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 6 ... 2. CSF3R
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3 |
ADRA1D
💬3. ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, ... | Ephedrine
Ephedrine
💬3. ADRA1D
| Ephedrine | 1件: 11 11 💬3. ADRA1D
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 4 |
ADRA1B
💬4. ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, ... | Ephedrine
Ephedrine
💬4. ADRA1B
| Ephedrine | 1件: 11 11 💬4. ADRA1B
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 5 |
ADRA1A
💬5. ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, ... | Ephedrine
Ephedrine
💬5. ADRA1A
| Ephedrine | 1件: 11 11 💬5. ADRA1A
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 6 |
ADRA2A
💬6. ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | Ephedrine
Ephedrine
💬6. ADRA2A
| Ephedrine | 1件: 11 11 💬6. ADRA2A
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 7 |
ADRA2A
💬7. ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | Apraclonidine
Apraclonidine
💬7. ADRA2A
| Apraclonidine | 1件: 11 11 💬7. ADRA2A
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 8 |
ADRA2B
💬8. ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | Ephedrine
Ephedrine
💬8. ADRA2B
| Ephedrine | 1件: 11 11 💬8. ADRA2B
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 9 |
ADRA2B
💬9. ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | Apraclonidine
Apraclonidine
💬9. ADRA2B
| Apraclonidine | 1件: 11 11 💬9. ADRA2B
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 10 |
ADRA2C
💬10. ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | Ephedrine
Ephedrine
💬10. ADRA2C
| Ephedrine | 1件: 11 11 💬10. ADRA2C
|